19275-46-8Relevant articles and documents
Synthesis of xanthone derivatives based on α-mangostin and their biological evaluation for anti-cancer agents
Fei, Xiang,Jo, Minmi,Lee, Bit,Han, Sang-Bae,Lee, Kiho,Jung, Jae-Kyung,Seo, Seung-Yong,Kwak, Young-Shin
, p. 2062 - 2065 (2014)
A xanthone-derived natural product, α-mangostin is isolated from various parts of the mangosteen, Garcinia mangostana L. (Clusiaceae), a well-known tropical fruit. Novel xanthone derivatives based on α-mangostin were synthesized and evaluated as anti-cancer agents by cytotoxicity activity screening using 5 human cancer cell lines. Some of these analogs had potent to moderate inhibitory activities. The structure-activity relationship studies revealed that phenol groups on C3 and C6 are critical to anti-proliferative activity and C4 modification is capable to improve both anti-cancer activity and drug-like properties. Our findings provide new possibilities for further explorations to improve potency.
Modified tetra-oxygenated xanthones analogues as anti-MRSA and P. aeruginosa agent and their synergism with vancomycin
Boonnak, Nawong,Chantrapromma, Suchada,Kaewpiboon, Chutima,Sathirakul, Korbtham
supporting information, (2020/08/21)
Five isolated xanthones from the C. cochinchinense and G. mangostana were evaluated and tested for antibacterial activities. Isolated 4 and 5 exhibited potent anti-MRSA and P. aeruginosa activity, but showed poor pharmacokinetic properties via ADMET prediction. It led us to improve pharmacokinetic properties of 4 and 5 by partially modifying them in acidic condition yielding fourteen analogues. It was found that analogues 4b, 4d and 5b possessed proper pharmacokinetic properties, while only 4b exhibited the best anti-MRSA and P. aeruginosa activity. The SEM results indicated that 4b may interact with or damage the cell wall of MRSA and P. aeruginosa. Moreover, a combination of 4b and vancomycin exhibits synergistic effect against both MRSA and P. aeruginosa at MIC value of 4.98 (MIC = 18.75 μg/mL for 4b) and 9.52 μg/mL (MIC = 75 μg/mL for 4b), respectively.
Novel Xanthone Derivatives and Composition for Treating Cancer Comprising the Same as Active Ingredient
-
Paragraph 0093; 0094, (2016/10/08)
The present invention relates to a novel xanthone derivative compound, and an anticancer composition comprising the compound as an active ingredient. The xanthone derivative compound of the present invention exhibits excellent anticancer activities against various human cancer cells and remarkably enhanced water solubility compared to an alpha-mangostin compound which is a parent compound. Therefore, the xanthone derivative compound of the present invention can be developed into anticancer drugs having excellent activities.COPYRIGHT KIPO 2016